BWA
VYGR icon

Basecamp Wealth Advisors’s Voyager Therapeutics VYGR Stock Holding History

Basecamp Wealth Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298 Hold
85
– – ﹤0.01% 1703
2026
Q1 		$328 Sell
85
-56
-40% -$220 ﹤0.01% 1804
2025
Q4 		$554 Buy
+141
New +$624 ﹤0.01% 1610

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Basecamp Wealth Advisors's VYGR Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Voyager Therapeutics (VYGR) position steady in Q2 2026 at 85 shares worth $298. The position accounts for ﹤0.01% of the portfolio, ranked #1703.

Basecamp Wealth Advisors first reported a position in VYGR in Q4 2025 and has held it in 3 quarters since. The position peaked at $554 in Q4 2025. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Basecamp Wealth Advisors held 85 shares of Voyager Therapeutics worth $298 as of Q2 2026.
  • Basecamp Wealth Advisors left its Voyager Therapeutics share count unchanged in Q2 2026.
  • Voyager Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1703 holding.
  • Basecamp Wealth Advisors first reported a position in Voyager Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Voyager Therapeutics position peaked at $554 in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.